HSE - PCRS

Application Details

HSE Application ID

HSE100019

HTA Number

25015

HTA Link

https://www.ncpe.ie/ocrelizumab-subcutaneous-ocrevus-sc-hta-id-25015/

Drug

ocrelizumab

Brand

Ocrevus®

Applicant

Roche

Approved Indication

For the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
For the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

Application Date

18/02/2025

Marketing Authorisation Date

20/06/2024

Application Status

HSE Approval Letter Issued to Applicant

01/09/2025

Reviewed by HSE Drugs Group

08/07/2025

HSE Drugs Group Review Pending

25/03/2025

Proposal from Applicant Under Review

20/03/2025

Rapid Review Completed

20/03/2025

Rapid Review Commissioned

18/02/2025

Pricing and Reimbursement Application Complete

18/02/2025

Applicant Meeting Held with CPU

12/12/2024

New Search